Proposed Collection; 60-Day Comment Request; NCI Cancer Genetics Services Directory Web-Based Application and Update Mailer (National Cancer Institute), 41971-41972 [2017-18667]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 170 / Tuesday, September 5, 2017 / Notices
Facsimile: (240)-276–5504 Email:
greenejaime@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
mstockstill on DSK30JT082PROD with NOTICES
EP Patent 1999277 (Application No.
07753436.0) filed 19 March 2007, titled
‘‘Apparatus for biosensor microarrays based
on carbon nanotube transistors having
biological probe materials, method for its
production and method of electronically
detecting a biological target material’’,
validated in FR, DE, IE, and GB, HHS
Reference No.: E–056–2007/0–EP–04;
Australia Patent 2007227415 (Application
No. 2007227415) filed 10/16/08, titled
‘‘Apparatus for microarray binding sensors
having biological probe materials using
carbon nanotube transistors’’, HHS Reference
No.: E–056–2007/0–AU–05;
Canada Patent 2646465 (Application No.
2646465) filed 03/19/07, titled ‘‘Apparatus
for microarray binding sensors having
biological probe materials using carbon
nanotube transistors’’, HHS Reference No.: E–
056–2007/0–CA–06;
Japan Patent 5048752 (Application No.
2009–501490) filed 03/19/07, titled
‘‘Apparatus for microarray binding sensors
having biological probe materials using
carbon nanotube transistors’’, HHS Reference
No.: E–056–2007/0–JP–07;
EP Patent 2570490 (Application No.
12160369.0) filed 03/19/07, titled ‘‘Apparatus
for microarray binding sensors having
biological probe materials using carbon
nanotube transistors’’, validated in FR, DE,
and GB. HHS Reference No.: E–056–2007/0–
EP–08;
U.S. Patent 8,017,938 (Application No. 11/
723,369), filed 19 March 2007, titled
‘‘Apparatus for Microarray Binding Sensors
Having Biological Probe Materials Using
Carbon Nanotube Transistors’’, HHS Ref. No.:
E–056–2007/0–US–03; and
PCT Application No. PCT/US2007/06809,
filed 19 March 2007, now abandoned, titled
‘‘Apparatus for Microarray Binding Sensors
Having Biological Probe Materials Using
Carbon Nanotube Transistors’’, HHS Ref. No.:
E–056–2007/0–PCT–02.
U.S. Provisional Patent Application No.
60/743,524, filed 17 March 2006, now
abandoned, titled ‘‘Apparatus for Microarray
DNA Binding Sensors Using Carbon
Nanotube Transistors’’, HHS Ref. No.: E–056–
2007/0–US–01.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘The
development of an FDA-approved or
cleared in vitro diagnostic for the
detection of hematological
malignancies, wherein nucleic acids
encoding one or more of the following
genes are detected: (1) BCR–ABL, (2)
FLT3, (3) Btk, (4) Alk, (5) Bcl–2, (6) Akt,
and (7) PI3K.’’
This technology discloses a
microarray apparatus that uses carbon
VerDate Sep<11>2014
17:43 Sep 01, 2017
Jkt 241001
nanotubes transistors and electronic
circuitry to quantitatively measure
changes in gene expression levels.
Typically, microarrays are microscope
glass slides spotted with thousands of
different genes. The array does not have
built-in reader, and the detection is
performed using a fluorescence scanner
after hybridization with fluorescenttagged target DNA. For simple nucleic
acid detection, current methods rely
upon various combinations of
enzymatic amplification of nucleic acids
and fluorescent labeling of targets,
which entail enzymatic manipulation of
the nucleic acid being tested and
chemical labeling, respectively. These
methods are both time consuming and
afford limited sensitivity. In cases where
microarray technology is used as a tool
for monitoring gene expression patterns
and profiling of micro RNA (miRNA) in
normal and cancerous tissue,
quantification of changes has typically
been optically-based. While this
technique is highly sensitive, use of
optical methods impedes progress in
both system miniaturization and in
direct interfacing with data collection
electronics.
To overcome the limitation of current
microarray technologies, the inventors
have developed a highly sensitive
microarray apparatus that uses carbon
nanotube transistors for the electronic
detection of biological probe-target
binding. The present invention provides
an apparatus for biological target
material detection which uses an array
of carbon nanotube transistors, with
each being operated as a field effect
transistor. A single carbon nanotube
transistor is associated with a distinct
biological probe material. The current
versus voltage characteristics or
transconductance between the source
and drain electrodes is measured before
and after a binding event between the
biological probe and target materials. By
using a mathematical relationship, the
exact amount of target binding can be
extracted. Importantly, the present
apparatus offers a significant advantage
in simplicity of protocol as the method
used therewith does not require
chemical or enzymatic manipulation of
the target being detected.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
41971
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Exclusive
Commercialization Patent License
Agreement. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 25, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–18668 Filed 9–1–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; NCI Cancer Genetics
Services Directory Web-Based
Application and Update Mailer
(National Cancer Institute)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI) will
publish periodic summaries of propose
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
SUMMARY:
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Margaret Beckwith, Office of
Cancer Content, Office of
Communications and Public Liaison
(OCPL), 9609 Medical Center Drive,
Rockville, MD 20892 or call non-tollfree number 240–276–6600 or email
your request, including your address to:
nciocpl@mail.nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\05SEN1.SGM
05SEN1
41972
Federal Register / Vol. 82, No. 170 / Tuesday, September 5, 2017 / Notices
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimize the
burden of the collection of information
on those who are to respond, including
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Proposed Collection Title: NCI Cancer
Genetics Services Directory Web-Based
Application and Update Mailer, 0925–
professionals who provide services
related to cancer genetics. The
information collected on the application
form includes name, professional
qualifications, practice locations, and
the area of specialization. The
information is updated annually using a
Web-based update mailer that mirrors
the application form.
The NCI Cancer Genetics Services
Directory is a unique resource for cancer
patients and their families who are
looking for information about their
family risk of cancer and genetic
counseling. Collecting applicant
information and verifying it annually by
using the NCI Cancer Genetics Services
Directory Web-based Application Form
and Update Mailer is important for
providing this information to the public
and for keeping it current.
OMB approval is requested for 3 year.
There are no costs to respondents other
than their time. The total estimated
annualized burden hours are 180.
0639, Extension, National Cancer
Institute (NCI), National Institutes of
Health (NIH).
Need and Use of Information
Collection: The Office of
Communications and Public Liaison has
created the NCI Cancer Genetics
Services Directory on NCI’s Web site
Cancer.gov. This directory is a
searchable collection of information
about professionals who provide
services related to cancer genetics.
These services include cancer risk
assessment, genetic counseling, and
genetic susceptibility testing. The
professionals have applied to be in the
directory using an online application
form and have met basic criteria
outlined on the form.
There are currently 552 genetics
professionals listed in the directory.
Approximately 30–60 new professionals
are added to the directory each year.
The applicants are nurses, physicians,
genetic counselors, and other
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden
per response
(in hours)
Total annual
burden Hours
Form name
Type of respondent
Web-based Application Form ............
Web-based Update Mailer ................
Genetics Professional ......................
Genetics Professional ......................
60
600
1
1
30/60
15/60
30
150
Totals ..........................................
..........................................................
660
660
........................
180
Dated: August 21, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2017–18667 Filed 9–1–17; 8:45 am]
Room 4A29, MSC2479, Bethesda, MD
20892–2479; telephone: 301–402–5579.
A signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
BILLING CODE 4140–01–P
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
Availability for licensing U.S.
Government owned intellectual
property for commercial development.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by emailing the indicated
licensing contact at the National Heart,
Lung, and Blood, Office of Technology
Transfer and Development Office of
Technology Transfer, 31 Center Drive
mstockstill on DSK30JT082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:43 Sep 01, 2017
Jkt 241001
The
inventions listed below are owned by an
agency of the U.S. Government and are
available for licensing in the U.S. in
accordance with 35 U.S.C. 209 and 37
CFR part 404 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing. Technology description
follows.
Hybrid Computed Tomography
Scanning System
Description of Technology: The
invention relates to a combination
hybrid computed tomography (CT)
system that is particularly suited for
elucidating stages in pulmonary
diseases, notably cystic fibrosis and
lung cancer. Improved visualization of
lung parenchyma and the margins of
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
lung cysts and lung nodules (noninvasive ‘‘virtual biopsy’’) may provide
sufficient detail to distinguish the types
of cystic lesions and lung nodules such
that the typical lung tissue pathologic
biopsy would not be needed to make a
diagnosis. The system includes placing
one or more x-ray detector panels near
the patient’s body initially outside the
view of a CT scanner and then moved
into place for a secondary scan. An
initial low dose scan, CT scan or X-ray,
can be performed and if a highresolution CT scan is then necessary a
flat panel detector is positioned near the
area of interest. It is preferable that the
flat panel detector be transparent to
high-energy x-ray photons. The plurality
of acquired images are then
reconstructed into a low and highresolution image.
Potential Commercial Applications:
• Non-invasive lung biopsies
Development Stage:
• Early stage, no prototype.
Inventors: Han Wen (NHLBI)
Intellectual Property: HHS Reference
No. E–175–2017/0–US–01
• U.S. Provisional Patent Application
62/546,639 filed August 17, 2017.
E:\FR\FM\05SEN1.SGM
05SEN1
]]>Agencies
[Federal Register Volume 82, Number 170 (Tuesday, September 5, 2017)]
[Notices]
[Pages 41971-41972]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18667]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; NCI Cancer Genetics
Services Directory Web-Based Application and Update Mailer (National
Cancer Institute)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Cancer Institute (NCI) will publish
periodic summaries of propose projects to be submitted to the Office of
Management and Budget (OMB) for review and approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Margaret
Beckwith, Office of Cancer Content, Office of Communications and Public
Liaison (OCPL), 9609 Medical Center Drive, Rockville, MD 20892 or call
non-toll-free number 240-276-6600 or email your request, including your
address to: nciocpl@mail.nih.gov. Formal requests for additional plans
and instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: Written
[[Page 41972]]
comments and/or suggestions from the public and affected agencies are
invited to address one or more of the following points: (1) Whether the
proposed collection of information is necessary for the proper
performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) Ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) Ways to minimize the burden of the
collection of information on those who are to respond, including the
use of appropriate automated, electronic, mechanical, or other
technological collection techniques or other forms of information
technology.
Proposed Collection Title: NCI Cancer Genetics Services Directory
Web-Based Application and Update Mailer, 0925-0639, Extension, National
Cancer Institute (NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: The Office of
Communications and Public Liaison has created the NCI Cancer Genetics
Services Directory on NCI's Web site Cancer.gov. This directory is a
searchable collection of information about professionals who provide
services related to cancer genetics. These services include cancer risk
assessment, genetic counseling, and genetic susceptibility testing. The
professionals have applied to be in the directory using an online
application form and have met basic criteria outlined on the form.
There are currently 552 genetics professionals listed in the
directory. Approximately 30-60 new professionals are added to the
directory each year. The applicants are nurses, physicians, genetic
counselors, and other professionals who provide services related to
cancer genetics. The information collected on the application form
includes name, professional qualifications, practice locations, and the
area of specialization. The information is updated annually using a
Web-based update mailer that mirrors the application form.
The NCI Cancer Genetics Services Directory is a unique resource for
cancer patients and their families who are looking for information
about their family risk of cancer and genetic counseling. Collecting
applicant information and verifying it annually by using the NCI Cancer
Genetics Services Directory Web-based Application Form and Update
Mailer is important for providing this information to the public and
for keeping it current.
OMB approval is requested for 3 year. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 180.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Average burden
Form name Type of respondent Number of responses per per response Total annual
respondents respondent (in hours) burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Web-based Application Form..................... Genetics Professional.................. 60 1 30/60 30
Web-based Update Mailer........................ Genetics Professional.................. 600 1 15/60 150
---------------------------------------------------------------
Totals..................................... ....................................... 660 660 .............. 180
--------------------------------------------------------------------------------------------------------------------------------------------------------
Dated: August 21, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer Institute, National
Institutes of Health.
[FR Doc. 2017-18667 Filed 9-1-17; 8:45 am]
BILLING CODE 4140-01-P
